{"transactions":[{"id":885288,"issuer":{"id":5281,"kind":"organization","name":"Prime Medicine, Inc."},"owners":[{"id":64973,"kind":"person","name":"Alenson Carman","position":1,"cik":"0001688865","reported_name":"Alenson Carman","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2026-02-24T21:58:04.000Z","date":"2026-02-23","kind":"grant","planned":false,"acquired":true,"shares":140000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the shares underlying this option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of February 23, 2026, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":140000,"derivative":{"exercise_price":3.34,"expiration_date":"2036-02-23","underlying":"Common Stock","underlying_shares":140000},"source":{"system":"sec-edgar","filing":"0001628280-26-011181","document":"wk-form4_1771970281.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1894562/000162828026011181/wk-form4_1771970281.xml","form_type":"4"}},{"id":1074874,"issuer":{"id":5281,"kind":"organization","name":"Prime Medicine, Inc."},"owners":[{"id":64973,"kind":"person","name":"Alenson Carman","position":1,"cik":"0001688865","reported_name":"Alenson Carman","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2025-08-06T00:42:30.000Z","date":"2025-08-01","kind":"grant","planned":false,"acquired":true,"shares":90498,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of August 1, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the \"2019 Plan\") and/or the 2022 Stock Option and Incentive Plan (the \"2022 Plan\" and, together with the 2019 Plan, the \"Plans\"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of August 1, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the \"2019 Plan\") and/or the 2022 Stock Option and Incentive Plan (the \"2022 Plan\" and, together with the 2019 Plan, the \"Plans\"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2019 Plan and/or the 2022 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":90498,"derivative":{"exercise_price":4.04,"expiration_date":"2034-02-21","underlying":"Common Stock","underlying_shares":90498},"source":{"system":"sec-edgar","filing":"0001894562-25-000042","document":"wk-form4_1754440946.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1894562/000189456225000042/wk-form4_1754440946.xml","form_type":"4"}},{"id":1074873,"issuer":{"id":5281,"kind":"organization","name":"Prime Medicine, Inc."},"owners":[{"id":64973,"kind":"person","name":"Alenson Carman","position":1,"cik":"0001688865","reported_name":"Alenson Carman","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2025-08-06T00:42:30.000Z","date":"2025-08-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":90498,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of August 1, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the \"2019 Plan\") and/or the 2022 Stock Option and Incentive Plan (the \"2022 Plan\" and, together with the 2019 Plan, the \"Plans\"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of August 1, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the \"2019 Plan\") and/or the 2022 Stock Option and Incentive Plan (the \"2022 Plan\" and, together with the 2019 Plan, the \"Plans\"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2019 Plan and/or the 2022 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":8.49,"expiration_date":"2034-02-21","underlying":"Common Stock","underlying_shares":90498},"source":{"system":"sec-edgar","filing":"0001894562-25-000042","document":"wk-form4_1754440946.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1894562/000189456225000042/wk-form4_1754440946.xml","form_type":"4"}},{"id":1074872,"issuer":{"id":5281,"kind":"organization","name":"Prime Medicine, Inc."},"owners":[{"id":64973,"kind":"person","name":"Alenson Carman","position":1,"cik":"0001688865","reported_name":"Alenson Carman","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2025-08-06T00:42:30.000Z","date":"2025-08-01","kind":"grant","planned":false,"acquired":true,"shares":6254,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of August 1, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the \"2019 Plan\") and/or the 2022 Stock Option and Incentive Plan (the \"2022 Plan\" and, together with the 2019 Plan, the \"Plans\"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of August 1, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the \"2019 Plan\") and/or the 2022 Stock Option and Incentive Plan (the \"2022 Plan\" and, together with the 2019 Plan, the \"Plans\"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2019 Plan and/or the 2022 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":6254,"derivative":{"exercise_price":4.04,"expiration_date":"2033-04-18","underlying":"Common Stock","underlying_shares":6254},"source":{"system":"sec-edgar","filing":"0001894562-25-000042","document":"wk-form4_1754440946.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1894562/000189456225000042/wk-form4_1754440946.xml","form_type":"4"}},{"id":1074871,"issuer":{"id":5281,"kind":"organization","name":"Prime Medicine, Inc."},"owners":[{"id":64973,"kind":"person","name":"Alenson Carman","position":1,"cik":"0001688865","reported_name":"Alenson Carman","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2025-08-06T00:42:30.000Z","date":"2025-08-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":6254,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of August 1, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the \"2019 Plan\") and/or the 2022 Stock Option and Incentive Plan (the \"2022 Plan\" and, together with the 2019 Plan, the \"Plans\"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of August 1, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the \"2019 Plan\") and/or the 2022 Stock Option and Incentive Plan (the \"2022 Plan\" and, together with the 2019 Plan, the \"Plans\"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2019 Plan and/or the 2022 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":13.63,"expiration_date":"2033-04-18","underlying":"Common Stock","underlying_shares":6254},"source":{"system":"sec-edgar","filing":"0001894562-25-000042","document":"wk-form4_1754440946.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1894562/000189456225000042/wk-form4_1754440946.xml","form_type":"4"}},{"id":1074870,"issuer":{"id":5281,"kind":"organization","name":"Prime Medicine, Inc."},"owners":[{"id":64973,"kind":"person","name":"Alenson Carman","position":1,"cik":"0001688865","reported_name":"Alenson Carman","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2025-08-06T00:42:30.000Z","date":"2025-08-01","kind":"grant","planned":false,"acquired":true,"shares":90498,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of August 1, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the \"2019 Plan\") and/or the 2022 Stock Option and Incentive Plan (the \"2022 Plan\" and, together with the 2019 Plan, the \"Plans\"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of August 1, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the \"2019 Plan\") and/or the 2022 Stock Option and Incentive Plan (the \"2022 Plan\" and, together with the 2019 Plan, the \"Plans\"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2019 Plan and/or the 2022 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":90498,"derivative":{"exercise_price":4.04,"expiration_date":"2033-03-31","underlying":"Common Stock","underlying_shares":90498},"source":{"system":"sec-edgar","filing":"0001894562-25-000042","document":"wk-form4_1754440946.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1894562/000189456225000042/wk-form4_1754440946.xml","form_type":"4"}},{"id":1074869,"issuer":{"id":5281,"kind":"organization","name":"Prime Medicine, Inc."},"owners":[{"id":64973,"kind":"person","name":"Alenson Carman","position":1,"cik":"0001688865","reported_name":"Alenson Carman","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2025-08-06T00:42:30.000Z","date":"2025-08-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":90498,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of August 1, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the \"2019 Plan\") and/or the 2022 Stock Option and Incentive Plan (the \"2022 Plan\" and, together with the 2019 Plan, the \"Plans\"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of August 1, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the \"2019 Plan\") and/or the 2022 Stock Option and Incentive Plan (the \"2022 Plan\" and, together with the 2019 Plan, the \"Plans\"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2019 Plan and/or the 2022 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":12.3,"expiration_date":"2033-03-31","underlying":"Common Stock","underlying_shares":90498},"source":{"system":"sec-edgar","filing":"0001894562-25-000042","document":"wk-form4_1754440946.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1894562/000189456225000042/wk-form4_1754440946.xml","form_type":"4"}},{"id":1074868,"issuer":{"id":5281,"kind":"organization","name":"Prime Medicine, Inc."},"owners":[{"id":64973,"kind":"person","name":"Alenson Carman","position":1,"cik":"0001688865","reported_name":"Alenson Carman","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2025-08-06T00:42:30.000Z","date":"2025-08-01","kind":"grant","planned":false,"acquired":true,"shares":16083,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of August 1, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the \"2019 Plan\") and/or the 2022 Stock Option and Incentive Plan (the \"2022 Plan\" and, together with the 2019 Plan, the \"Plans\"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of August 1, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the \"2019 Plan\") and/or the 2022 Stock Option and Incentive Plan (the \"2022 Plan\" and, together with the 2019 Plan, the \"Plans\"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2019 Plan and/or the 2022 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":16083,"derivative":{"exercise_price":4.04,"expiration_date":"2032-01-24","underlying":"Common Stock","underlying_shares":16083},"source":{"system":"sec-edgar","filing":"0001894562-25-000042","document":"wk-form4_1754440946.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1894562/000189456225000042/wk-form4_1754440946.xml","form_type":"4"}},{"id":1074867,"issuer":{"id":5281,"kind":"organization","name":"Prime Medicine, Inc."},"owners":[{"id":64973,"kind":"person","name":"Alenson Carman","position":1,"cik":"0001688865","reported_name":"Alenson Carman","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2025-08-06T00:42:30.000Z","date":"2025-08-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":16083,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of August 1, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the \"2019 Plan\") and/or the 2022 Stock Option and Incentive Plan (the \"2022 Plan\" and, together with the 2019 Plan, the \"Plans\"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of August 1, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the \"2019 Plan\") and/or the 2022 Stock Option and Incentive Plan (the \"2022 Plan\" and, together with the 2019 Plan, the \"Plans\"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2019 Plan and/or the 2022 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":10.92,"expiration_date":"2032-01-24","underlying":"Common Stock","underlying_shares":16083},"source":{"system":"sec-edgar","filing":"0001894562-25-000042","document":"wk-form4_1754440946.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1894562/000189456225000042/wk-form4_1754440946.xml","form_type":"4"}},{"id":1236183,"issuer":{"id":5281,"kind":"organization","name":"Prime Medicine, Inc."},"owners":[{"id":64973,"kind":"person","name":"Alenson Carman","position":1,"cik":"0001688865","reported_name":"Alenson Carman","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2025-03-04T01:18:26.000Z","date":"2025-02-27","kind":"grant","planned":false,"acquired":true,"shares":90500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the shares underlying this option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of February 27, 2025, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":90500,"derivative":{"exercise_price":2.42,"expiration_date":"2035-02-27","underlying":"Common Stock","underlying_shares":90500},"source":{"system":"sec-edgar","filing":"0001894562-25-000012","document":"wk-form4_1741051100.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1894562/000189456225000012/wk-form4_1741051100.xml","form_type":"4"}},{"id":1622884,"issuer":{"id":5281,"kind":"organization","name":"Prime Medicine, Inc."},"owners":[{"id":64973,"kind":"person","name":"Alenson Carman","position":1,"cik":"0001688865","reported_name":"Alenson Carman","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2024-02-23T22:01:25.000Z","date":"2024-02-21","kind":"grant","planned":false,"acquired":true,"shares":90498,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the shares underlying this option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of February 21, 2024, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":90498,"derivative":{"exercise_price":8.49,"expiration_date":"2034-02-21","underlying":"Common Stock","underlying_shares":90498},"source":{"system":"sec-edgar","filing":"0001894562-24-000010","document":"wk-form4_1708725660.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1894562/000189456224000010/wk-form4_1708725660.xml","form_type":"4"}},{"id":1916577,"issuer":{"id":5281,"kind":"organization","name":"Prime Medicine, Inc."},"owners":[{"id":64973,"kind":"person","name":"Alenson Carman","position":1,"cik":"0001688865","reported_name":"Alenson Carman","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2023-04-20T20:28:23.000Z","date":"2023-04-18","kind":"grant","planned":false,"acquired":true,"shares":6254,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the shares underlying this option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of March 31, 2023, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":6254,"derivative":{"exercise_price":13.63,"expiration_date":"2033-04-18","underlying":"Common Stock","underlying_shares":6254},"source":{"system":"sec-edgar","filing":"0001894562-23-000010","document":"wf-form4_168202248714996.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1894562/000189456223000010/wf-form4_168202248714996.xml","form_type":"4"}},{"id":1929022,"issuer":{"id":5281,"kind":"organization","name":"Prime Medicine, Inc."},"owners":[{"id":64973,"kind":"person","name":"Alenson Carman","position":1,"cik":"0001688865","reported_name":"Alenson Carman","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2023-04-05T00:22:15.000Z","date":"2023-03-31","kind":"grant","planned":false,"acquired":true,"shares":90498,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the shares underlying this option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of March 31, 2023, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":90498,"derivative":{"exercise_price":12.3,"expiration_date":"2033-03-31","underlying":"Common Stock","underlying_shares":90498},"source":{"system":"sec-edgar","filing":"0001894562-23-000001","document":"wf-form4_168065412225046.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1894562/000189456223000001/wf-form4_168065412225046.xml","form_type":"4"}},{"id":2657162,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":64973,"kind":"person","name":"Alenson Carman","position":1,"cik":"0001688865","reported_name":"Alenson Carman","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Stock option (right to buy)","published_at":"2021-06-23T17:28:44.000Z","date":"2021-06-21","kind":"exercise","acquired":false,"shares":1777,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on February 14, 2020. The shares underlying this option vest as to 25% of the underlying shares on February 14, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter."}],"balance_after":3555,"derivative":{"exercise_price":51.51,"expiration_date":"2030-02-14","underlying":"Common stock","underlying_shares":1777},"source":{"system":"sec-edgar","filing":"0001439222-21-000060","document":"wf-form4_162448370684332.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1688865/000143922221000060/wf-form4_162448370684332.xml","form_type":"4"}},{"id":2657161,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":64973,"kind":"person","name":"Alenson Carman","position":1,"cik":"0001688865","reported_name":"Alenson Carman","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Common stock","published_at":"2021-06-23T17:28:44.000Z","date":"2021-06-21","kind":"sale","acquired":false,"shares":1777,"price":61.61,"value":109480.97,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001439222-21-000060","document":"wf-form4_162448370684332.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1688865/000143922221000060/wf-form4_162448370684332.xml","form_type":"4"}},{"id":2657160,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":64973,"kind":"person","name":"Alenson Carman","position":1,"cik":"0001688865","reported_name":"Alenson Carman","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Common stock","published_at":"2021-06-23T17:28:44.000Z","date":"2021-06-21","kind":"exercise","acquired":true,"shares":1777,"price":51.51,"value":91533.27,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":1777,"source":{"system":"sec-edgar","filing":"0001439222-21-000060","document":"wf-form4_162448370684332.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1688865/000143922221000060/wf-form4_162448370684332.xml","form_type":"4"}},{"id":2744010,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":64973,"kind":"person","name":"Alenson Carman","position":1,"cik":"0001688865","reported_name":"Alenson Carman","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Common stock","published_at":"2021-04-20T16:10:08.000Z","date":"2021-04-16","kind":"sale","acquired":false,"shares":1118,"price":55.89,"value":62485.02,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001439222-21-000035","document":"wf-form4_161894939327254.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1688865/000143922221000035/wf-form4_161894939327254.xml","form_type":"4"}},{"id":2747158,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":64973,"kind":"person","name":"Alenson Carman","position":1,"cik":"0001688865","reported_name":"Alenson Carman","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Common stock","published_at":"2021-04-16T16:33:29.000Z","date":"2021-04-15","kind":"sale","acquired":false,"shares":991,"price":54,"value":53514.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 314 shares purchased through the Company's employee stock purchase plan."}],"balance_after":1118,"source":{"system":"sec-edgar","filing":"0001439222-21-000034","document":"wf-form4_161860518490311.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1688865/000143922221000034/wf-form4_161860518490311.xml","form_type":"4"}},{"id":2836008,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":64973,"kind":"person","name":"Alenson Carman","position":1,"cik":"0001688865","reported_name":"Alenson Carman","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Restricted stock units","published_at":"2021-02-24T16:12:21.000Z","date":"2021-02-22","kind":"exercise","acquired":false,"shares":692,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units were granted on February 22, 2019. Beginning on February 22, 2020, the shares underlying the restricted stock units will vest in three equal annual installments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units were granted on February 22, 2019. Beginning on February 22, 2020, the shares underlying the restricted stock units will vest in three equal annual installments."}],"balance_after":691,"derivative":{"underlying":"Common stock","underlying_shares":692},"source":{"system":"sec-edgar","filing":"0001439222-21-000021","document":"wf-form4_161420111004318.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1688865/000143922221000021/wf-form4_161420111004318.xml","form_type":"4"}},{"id":2836007,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":64973,"kind":"person","name":"Alenson Carman","position":1,"cik":"0001688865","reported_name":"Alenson Carman","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Common stock","published_at":"2021-02-24T16:12:21.000Z","date":"2021-02-22","kind":"tax_withholding","acquired":false,"shares":199,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":1795,"source":{"system":"sec-edgar","filing":"0001439222-21-000021","document":"wf-form4_161420111004318.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1688865/000143922221000021/wf-form4_161420111004318.xml","form_type":"4"}},{"id":2836006,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":64973,"kind":"person","name":"Alenson Carman","position":1,"cik":"0001688865","reported_name":"Alenson Carman","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Common stock","published_at":"2021-02-24T16:12:21.000Z","date":"2021-02-22","kind":"exercise","acquired":true,"shares":692,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":1994,"source":{"system":"sec-edgar","filing":"0001439222-21-000021","document":"wf-form4_161420111004318.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1688865/000143922221000021/wf-form4_161420111004318.xml","form_type":"4"}},{"id":2854880,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":64973,"kind":"person","name":"Alenson Carman","position":1,"cik":"0001688865","reported_name":"Alenson Carman","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Restricted stock units","published_at":"2021-02-17T16:13:13.000Z","date":"2021-02-16","kind":"exercise","acquired":false,"shares":790,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units were granted on February 16,2018. The shares underlying the restricted stock units will vest in three equal annual installments on February 16, 2019, 2020 and 2021."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units were granted on February 16,2018. The shares underlying the restricted stock units will vest in three equal annual installments on February 16, 2019, 2020 and 2021."}],"balance_after":0,"derivative":{"underlying":"Common stock","underlying_shares":790},"source":{"system":"sec-edgar","filing":"0001439222-21-000010","document":"wf-form4_161359638023953.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1688865/000143922221000010/wf-form4_161359638023953.xml","form_type":"4"}},{"id":2854879,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":64973,"kind":"person","name":"Alenson Carman","position":1,"cik":"0001688865","reported_name":"Alenson Carman","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Restricted stock units","published_at":"2021-02-17T16:13:13.000Z","date":"2021-02-14","kind":"exercise","acquired":false,"shares":889,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units were granted on February 14, 2020. Beginning on February 14, 2021, the shares underlying the restricted stock units will vest in three equal annual installments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units were granted on February 14, 2020. Beginning on February 14, 2021, the shares underlying the restricted stock units will vest in three equal annual installments."}],"balance_after":1777,"derivative":{"underlying":"Common stock","underlying_shares":889},"source":{"system":"sec-edgar","filing":"0001439222-21-000010","document":"wf-form4_161359638023953.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1688865/000143922221000010/wf-form4_161359638023953.xml","form_type":"4"}},{"id":2854878,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":64973,"kind":"person","name":"Alenson Carman","position":1,"cik":"0001688865","reported_name":"Alenson Carman","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Common stock","published_at":"2021-02-17T16:13:13.000Z","date":"2021-02-16","kind":"tax_withholding","acquired":false,"shares":561,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":1302,"source":{"system":"sec-edgar","filing":"0001439222-21-000010","document":"wf-form4_161359638023953.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1688865/000143922221000010/wf-form4_161359638023953.xml","form_type":"4"}},{"id":2854877,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":64973,"kind":"person","name":"Alenson Carman","position":1,"cik":"0001688865","reported_name":"Alenson Carman","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Common stock","published_at":"2021-02-17T16:13:13.000Z","date":"2021-02-16","kind":"exercise","acquired":true,"shares":790,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":1863,"source":{"system":"sec-edgar","filing":"0001439222-21-000010","document":"wf-form4_161359638023953.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1688865/000143922221000010/wf-form4_161359638023953.xml","form_type":"4"}},{"id":2854876,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":64973,"kind":"person","name":"Alenson Carman","position":1,"cik":"0001688865","reported_name":"Alenson Carman","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Common stock","published_at":"2021-02-17T16:13:13.000Z","date":"2021-02-14","kind":"exercise","acquired":true,"shares":889,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":1073,"source":{"system":"sec-edgar","filing":"0001439222-21-000010","document":"wf-form4_161359638023953.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1688865/000143922221000010/wf-form4_161359638023953.xml","form_type":"4"}},{"id":2863435,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":64973,"kind":"person","name":"Alenson Carman","position":1,"cik":"0001688865","reported_name":"Alenson Carman","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Stock option (right to buy)","published_at":"2021-02-12T16:22:02.000Z","date":"2021-02-10","kind":"grant","acquired":true,"shares":2961,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on February 10, 2021. The shares underlying this option vest as to 25% of the underlying shares on February 10, 2022, with the remaining 75% vesting in 36 equal monthly installments thereafter."}],"balance_after":2961,"derivative":{"exercise_price":56.68,"expiration_date":"2031-02-10","underlying":"Common stock","underlying_shares":2961},"source":{"system":"sec-edgar","filing":"0001439222-21-000003","document":"wf-form4_161316487303183.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1688865/000143922221000003/wf-form4_161316487303183.xml","form_type":"4"}},{"id":2863434,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":64973,"kind":"person","name":"Alenson Carman","position":1,"cik":"0001688865","reported_name":"Alenson Carman","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Restricted stock units","published_at":"2021-02-12T16:22:02.000Z","date":"2021-02-10","kind":"grant","acquired":true,"shares":5922,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units were granted on February 10, 2021. Beginning on February 10, 2022, the shares underlying the restricted stock units will vest in three equal annual installments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units were granted on February 10, 2021. Beginning on February 10, 2022, the shares underlying the restricted stock units will vest in three equal annual installments."}],"balance_after":5922,"derivative":{"underlying":"Common stock","underlying_shares":5922},"source":{"system":"sec-edgar","filing":"0001439222-21-000003","document":"wf-form4_161316487303183.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1688865/000143922221000003/wf-form4_161316487303183.xml","form_type":"4"}},{"id":3004149,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":64973,"kind":"person","name":"Alenson Carman","position":1,"cik":"0001688865","reported_name":"Alenson Carman","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Restricted stock units","published_at":"2020-10-19T16:38:22.000Z","date":"2020-10-15","kind":"grant","acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units were granted on October 15, 2020. The shares underlying the restricted stock units will vest in full on October 15, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units were granted on October 15, 2020. The shares underlying the restricted stock units will vest in full on October 15, 2022."}],"balance_after":5000,"derivative":{"underlying":"Common stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001439222-20-000063","document":"wf-form4_160313988956166.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1688865/000143922220000063/wf-form4_160313988956166.xml","form_type":"4"}},{"id":3037790,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":64973,"kind":"person","name":"Alenson Carman","position":1,"cik":"0001688865","reported_name":"Alenson Carman","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Common stock","published_at":"2020-09-04T16:24:10.000Z","date":"2020-09-02","kind":"sale","acquired":false,"shares":250,"price":39.93,"value":9982.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F2","text":"Reflects shares purchased through the Company's employee stock purchase plan."}],"balance_after":184,"source":{"system":"sec-edgar","filing":"0001439222-20-000061","document":"wf-form4_159925103182387.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1688865/000143922220000061/wf-form4_159925103182387.xml","form_type":"4"}},{"id":3227696,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":64973,"kind":"person","name":"Alenson Carman","position":1,"cik":"0001688865","reported_name":"Alenson Carman","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Common stock","published_at":"2020-03-04T17:08:37.000Z","date":"2020-03-02","kind":"sale","acquired":false,"shares":345,"price":47.3,"value":16318.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F2","text":"Reflects shares purchased through the Company's employee stock purchase plan."}],"balance_after":184,"source":{"system":"sec-edgar","filing":"0001439222-20-000027","document":"wf-form4_158335970016750.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1688865/000143922220000027/wf-form4_158335970016750.xml","form_type":"4"}},{"id":3241320,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":64973,"kind":"person","name":"Alenson Carman","position":1,"cik":"0001688865","reported_name":"Alenson Carman","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Common stock","published_at":"2020-02-28T16:17:04.000Z","date":"2020-02-26","kind":"sale","acquired":false,"shares":472,"price":47.12,"value":22240.64,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":184,"source":{"system":"sec-edgar","filing":"0001439222-20-000025","document":"wf-form4_158292460758493.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1688865/000143922220000025/wf-form4_158292460758493.xml","form_type":"4"}},{"id":3249520,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":64973,"kind":"person","name":"Alenson Carman","position":1,"cik":"0001688865","reported_name":"Alenson Carman","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Restricted stock units","published_at":"2020-02-25T16:23:48.000Z","date":"2020-02-22","kind":"exercise","acquired":false,"shares":691,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units were granted on February 22, 2019. Beginning on February 22, 2020, the shares underlying the restricted stock units will vest in three equal annual installments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units were granted on February 22, 2019. Beginning on February 22, 2020, the shares underlying the restricted stock units will vest in three equal annual installments."}],"balance_after":1383,"derivative":{"underlying":"Common stock","underlying_shares":691},"source":{"system":"sec-edgar","filing":"0001439222-20-000021","document":"wf-form4_158266581146076.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1688865/000143922220000021/wf-form4_158266581146076.xml","form_type":"4"}},{"id":3249519,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":64973,"kind":"person","name":"Alenson Carman","position":1,"cik":"0001688865","reported_name":"Alenson Carman","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Common stock","published_at":"2020-02-25T16:23:48.000Z","date":"2020-02-24","kind":"tax_withholding","acquired":false,"shares":219,"price":48.66,"value":10656.54,"ownership":{"direct":true},"balance_after":656,"source":{"system":"sec-edgar","filing":"0001439222-20-000021","document":"wf-form4_158266581146076.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1688865/000143922220000021/wf-form4_158266581146076.xml","form_type":"4"}},{"id":3249518,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":64973,"kind":"person","name":"Alenson Carman","position":1,"cik":"0001688865","reported_name":"Alenson Carman","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Common stock","published_at":"2020-02-25T16:23:48.000Z","date":"2020-02-22","kind":"exercise","acquired":true,"shares":691,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."}],"balance_after":875,"source":{"system":"sec-edgar","filing":"0001439222-20-000021","document":"wf-form4_158266581146076.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1688865/000143922220000021/wf-form4_158266581146076.xml","form_type":"4"}},{"id":3253123,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":64973,"kind":"person","name":"Alenson Carman","position":1,"cik":"0001688865","reported_name":"Alenson Carman","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Common stock","published_at":"2020-02-24T16:02:32.000Z","date":"2020-02-20","kind":"sale","acquired":false,"shares":2427,"price":53.37,"value":129528.99,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $53.25 to $53.58. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price."}],"balance_after":184,"source":{"system":"sec-edgar","filing":"0001439222-20-000020","document":"wf-form4_158257813545803.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1688865/000143922220000020/wf-form4_158257813545803.xml","form_type":"4"}},{"id":3263553,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":64973,"kind":"person","name":"Alenson Carman","position":1,"cik":"0001688865","reported_name":"Alenson Carman","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Restricted stock units","published_at":"2020-02-19T16:55:21.000Z","date":"2020-02-16","kind":"exercise","acquired":false,"shares":2800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"All of the restricted stock units will vest on February 16, 2020. Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"All of the restricted stock units will vest on February 16, 2020. Vested shares will be delivered to the reporting person within three business days after such shares become vested."}],"balance_after":0,"derivative":{"underlying":"Common stock","underlying_shares":2800},"source":{"system":"sec-edgar","filing":"0001439222-20-000019","document":"wf-form4_158214930367652.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1688865/000143922220000019/wf-form4_158214930367652.xml","form_type":"4"}},{"id":3263552,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":64973,"kind":"person","name":"Alenson Carman","position":1,"cik":"0001688865","reported_name":"Alenson Carman","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Restricted stock units","published_at":"2020-02-19T16:55:21.000Z","date":"2020-02-16","kind":"exercise","acquired":false,"shares":790,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The restricted stock units were granted on February 16, 2018. The shares underlying the restricted stock units will vest in three equal annual installments on February 16, 2019, 2020 and 2021. Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The restricted stock units were granted on February 16, 2018. The shares underlying the restricted stock units will vest in three equal annual installments on February 16, 2019, 2020 and 2021. Vested shares will be delivered to the reporting person within three business days after such shares become vested."}],"balance_after":790,"derivative":{"underlying":"Common stock","underlying_shares":790},"source":{"system":"sec-edgar","filing":"0001439222-20-000019","document":"wf-form4_158214930367652.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1688865/000143922220000019/wf-form4_158214930367652.xml","form_type":"4"}},{"id":3263551,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":64973,"kind":"person","name":"Alenson Carman","position":1,"cik":"0001688865","reported_name":"Alenson Carman","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Stock option (right to buy)","published_at":"2020-02-19T16:55:21.000Z","date":"2020-02-14","kind":"grant","acquired":true,"shares":5332,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option was granted on February 14, 2020. The shares underlying this option vest as to 25% of the underlying shares on February 14, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter."}],"balance_after":5332,"derivative":{"exercise_price":51.51,"expiration_date":"2030-02-14","underlying":"Common stock","underlying_shares":5332},"source":{"system":"sec-edgar","filing":"0001439222-20-000019","document":"wf-form4_158214930367652.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1688865/000143922220000019/wf-form4_158214930367652.xml","form_type":"4"}},{"id":3263550,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":64973,"kind":"person","name":"Alenson Carman","position":1,"cik":"0001688865","reported_name":"Alenson Carman","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Restricted stock unit","published_at":"2020-02-19T16:55:21.000Z","date":"2020-02-14","kind":"grant","acquired":true,"shares":4800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units were granted on February 14, 2020. The shares underlying the restricted stock units will vest in full on February 14, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units were granted on February 14, 2020. The shares underlying the restricted stock units will vest in full on February 14, 2022."}],"balance_after":4800,"derivative":{"underlying":"Common stock","underlying_shares":4800},"source":{"system":"sec-edgar","filing":"0001439222-20-000019","document":"wf-form4_158214930367652.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1688865/000143922220000019/wf-form4_158214930367652.xml","form_type":"4"}},{"id":3263549,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":64973,"kind":"person","name":"Alenson Carman","position":1,"cik":"0001688865","reported_name":"Alenson Carman","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Restricted stock units","published_at":"2020-02-19T16:55:21.000Z","date":"2020-02-14","kind":"grant","acquired":true,"shares":2666,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units were granted on February 14, 2020. Beginning on February, 2021, the shares underlying the restricted stock units will vest in three equal annual installments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units were granted on February 14, 2020. Beginning on February, 2021, the shares underlying the restricted stock units will vest in three equal annual installments."}],"balance_after":2666,"derivative":{"underlying":"Common stock","underlying_shares":2666},"source":{"system":"sec-edgar","filing":"0001439222-20-000019","document":"wf-form4_158214930367652.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1688865/000143922220000019/wf-form4_158214930367652.xml","form_type":"4"}},{"id":3263548,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":64973,"kind":"person","name":"Alenson Carman","position":1,"cik":"0001688865","reported_name":"Alenson Carman","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Common stock","published_at":"2020-02-19T16:55:21.000Z","date":"2020-02-18","kind":"tax_withholding","acquired":false,"shares":1163,"price":52.01,"value":60487.63,"ownership":{"direct":true},"balance_after":2611,"source":{"system":"sec-edgar","filing":"0001439222-20-000019","document":"wf-form4_158214930367652.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1688865/000143922220000019/wf-form4_158214930367652.xml","form_type":"4"}},{"id":3263547,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":64973,"kind":"person","name":"Alenson Carman","position":1,"cik":"0001688865","reported_name":"Alenson Carman","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Common stock","published_at":"2020-02-19T16:55:21.000Z","date":"2020-02-16","kind":"exercise","acquired":true,"shares":2800,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."}],"balance_after":3774,"source":{"system":"sec-edgar","filing":"0001439222-20-000019","document":"wf-form4_158214930367652.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1688865/000143922220000019/wf-form4_158214930367652.xml","form_type":"4"}},{"id":3263546,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":64973,"kind":"person","name":"Alenson Carman","position":1,"cik":"0001688865","reported_name":"Alenson Carman","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Common stock","published_at":"2020-02-19T16:55:21.000Z","date":"2020-02-16","kind":"exercise","acquired":true,"shares":790,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."}],"balance_after":974,"source":{"system":"sec-edgar","filing":"0001439222-20-000019","document":"wf-form4_158214930367652.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1688865/000143922220000019/wf-form4_158214930367652.xml","form_type":"4"}},{"id":3329809,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":64973,"kind":"person","name":"Alenson Carman","position":1,"cik":"0001688865","reported_name":"Alenson Carman","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Common stock","published_at":"2019-12-30T16:08:19.000Z","date":"2019-12-26","kind":"sale","acquired":false,"shares":2950,"price":50.09,"value":147765.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $50.04 to $50.58. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes shares purchased through the Company's employee stock purchase plan."}],"balance_after":184,"source":{"system":"sec-edgar","filing":"0001439222-19-000030","document":"wf-form4_157774008262318.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1688865/000143922219000030/wf-form4_157774008262318.xml","form_type":"4"}},{"id":3632397,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":64973,"kind":"person","name":"Alenson Carman","position":1,"cik":"0001688865","reported_name":"Alenson Carman","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Restricted stock units","published_at":"2019-02-26T16:21:56.000Z","date":"2019-02-22","kind":"grant","acquired":true,"shares":2074,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units were granted on February 22, 2019. Beginning on February 22, 2020, the shares underlying the restricted stock units will vest in three equal annual installments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units were granted on February 22, 2019. Beginning on February 22, 2020, the shares underlying the restricted stock units will vest in three equal annual installments."}],"balance_after":2074,"derivative":{"underlying":"Common stock","underlying_shares":2074},"source":{"system":"sec-edgar","filing":"0001209191-19-013515","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1688865/000120919119013515/doc4.xml","form_type":"4"}},{"id":3632396,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":64973,"kind":"person","name":"Alenson Carman","position":1,"cik":"0001688865","reported_name":"Alenson Carman","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Stock option (right to buy)","published_at":"2019-02-26T16:21:56.000Z","date":"2019-02-22","kind":"grant","acquired":true,"shares":8295,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on February 22, 2019. The shares underlying this option vest as to 25% of the underlying shares on February 22, 2020, with the remaining 75% vesting in 36 equal monthly installments thereafter."}],"balance_after":8295,"derivative":{"exercise_price":58.86,"expiration_date":"2029-02-22","underlying":"Common stock","underlying_shares":8295},"source":{"system":"sec-edgar","filing":"0001209191-19-013515","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1688865/000120919119013515/doc4.xml","form_type":"4"}},{"id":3636022,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":64973,"kind":"person","name":"Alenson Carman","position":1,"cik":"0001688865","reported_name":"Alenson Carman","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Restricted stock units","published_at":"2019-02-25T16:03:05.000Z","date":"2019-02-21","kind":"exercise","acquired":false,"shares":3300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"All of the restricted stock units vested on February 21, 2019. Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"All of the restricted stock units vested on February 21, 2019. Vested shares will be delivered to the reporting person within three business days after such shares become vested."}],"balance_after":0,"derivative":{"underlying":"Common stock","underlying_shares":3300},"source":{"system":"sec-edgar","filing":"0001209191-19-012942","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1688865/000120919119012942/doc4.xml","form_type":"4"}},{"id":3636021,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":64973,"kind":"person","name":"Alenson Carman","position":1,"cik":"0001688865","reported_name":"Alenson Carman","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Common stock","published_at":"2019-02-25T16:03:05.000Z","date":"2019-02-21","kind":"tax_withholding","acquired":false,"shares":1016,"price":56.33,"value":57231.28,"ownership":{"direct":true},"balance_after":2796,"source":{"system":"sec-edgar","filing":"0001209191-19-012942","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1688865/000120919119012942/doc4.xml","form_type":"4"}},{"id":3636020,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":64973,"kind":"person","name":"Alenson Carman","position":1,"cik":"0001688865","reported_name":"Alenson Carman","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Common stock","published_at":"2019-02-25T16:03:05.000Z","date":"2019-02-21","kind":"exercise","acquired":true,"shares":3300,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."}],"balance_after":3812,"source":{"system":"sec-edgar","filing":"0001209191-19-012942","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1688865/000120919119012942/doc4.xml","form_type":"4"}},{"id":3646337,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":64973,"kind":"person","name":"Alenson Carman","position":1,"cik":"0001688865","reported_name":"Alenson Carman","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Restricted stock units","published_at":"2019-02-20T16:01:50.000Z","date":"2019-02-16","kind":"exercise","acquired":false,"shares":790,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units were granted on February 16, 2018. Beginning on February 16, 2019, the shares underlying the restricted stock units will vest in three equal annual installments. Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units were granted on February 16, 2018. Beginning on February 16, 2019, the shares underlying the restricted stock units will vest in three equal annual installments. Vested shares will be delivered to the reporting person within three business days after such shares become vested."}],"balance_after":1580,"derivative":{"underlying":"Common stock","underlying_shares":790},"source":{"system":"sec-edgar","filing":"0001209191-19-011483","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1688865/000120919119011483/doc4.xml","form_type":"4"}},{"id":3646336,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":64973,"kind":"person","name":"Alenson Carman","position":1,"cik":"0001688865","reported_name":"Alenson Carman","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Common stock","published_at":"2019-02-20T16:01:50.000Z","date":"2019-02-19","kind":"tax_withholding","acquired":false,"shares":278,"price":58.03,"value":16132.34,"ownership":{"direct":true},"balance_after":512,"source":{"system":"sec-edgar","filing":"0001209191-19-011483","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1688865/000120919119011483/doc4.xml","form_type":"4"}},{"id":3646335,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":64973,"kind":"person","name":"Alenson Carman","position":1,"cik":"0001688865","reported_name":"Alenson Carman","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Common stock","published_at":"2019-02-20T16:01:50.000Z","date":"2019-02-16","kind":"exercise","acquired":true,"shares":790,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."}],"balance_after":790,"source":{"system":"sec-edgar","filing":"0001209191-19-011483","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1688865/000120919119011483/doc4.xml","form_type":"4"}},{"id":3646334,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":64973,"kind":"person","name":"Alenson Carman","position":1,"cik":"0001688865","reported_name":"Alenson Carman","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Common stock","published_at":"2019-02-20T16:01:50.000Z","date":"2018-09-28","kind":"sale","acquired":false,"shares":152,"price":76.45,"value":11620.4,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is the weighted average of the shares sold.  The shares were sold at varying prices in the range of $76.44 to $76.47. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-19-011483","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1688865/000120919119011483/doc4.xml","form_type":"4"}},{"id":3822052,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":64973,"kind":"person","name":"Alenson Carman","position":1,"cik":"0001688865","reported_name":"Alenson Carman","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Stock option (right to buy)","published_at":"2018-09-07T16:18:24.000Z","date":"2018-09-05","kind":"exercise","acquired":false,"shares":312,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option was granted on November 7, 2016. The shares underlying this option vest as to 25% of the underlying shares on November 7, 2017, with the remaining 75% vesting in 36 equal monthly installments thereafter."}],"balance_after":12266,"derivative":{"exercise_price":52.29,"expiration_date":"2026-11-06","underlying":"Common stock","underlying_shares":312},"source":{"system":"sec-edgar","filing":"0001209191-18-050050","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1688865/000120919118050050/doc4.xml","form_type":"4"}},{"id":3822051,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":64973,"kind":"person","name":"Alenson Carman","position":1,"cik":"0001688865","reported_name":"Alenson Carman","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Common stock","published_at":"2018-09-07T16:18:24.000Z","date":"2018-09-05","kind":"sale","acquired":false,"shares":312,"price":83,"value":25896.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":152,"source":{"system":"sec-edgar","filing":"0001209191-18-050050","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1688865/000120919118050050/doc4.xml","form_type":"4"}},{"id":3822050,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":64973,"kind":"person","name":"Alenson Carman","position":1,"cik":"0001688865","reported_name":"Alenson Carman","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Common stock","published_at":"2018-09-07T16:18:24.000Z","date":"2018-09-05","kind":"exercise","acquired":true,"shares":312,"price":52.29,"value":16314.48,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 152 shares purchased through the Company's employee stock purchase plan."}],"balance_after":464,"source":{"system":"sec-edgar","filing":"0001209191-18-050050","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1688865/000120919118050050/doc4.xml","form_type":"4"}},{"id":3869395,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":64973,"kind":"person","name":"Alenson Carman","position":1,"cik":"0001688865","reported_name":"Alenson Carman","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Stock option (right to buy)","published_at":"2018-07-11T16:23:54.000Z","date":"2018-07-09","kind":"exercise","acquired":false,"shares":272,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on November 7, 2016. The shares underlying this option vest as to 25% of the underlying shares on November 7, 2017, with the remaining 75% vesting in 36 equal monthly installments thereafter."}],"balance_after":12578,"derivative":{"exercise_price":52.29,"expiration_date":"2026-11-06","underlying":"Common stock","underlying_shares":272},"source":{"system":"sec-edgar","filing":"0001209191-18-042326","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1688865/000120919118042326/doc4.xml","form_type":"4"}},{"id":3869394,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":64973,"kind":"person","name":"Alenson Carman","position":1,"cik":"0001688865","reported_name":"Alenson Carman","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Common stock","published_at":"2018-07-11T16:23:54.000Z","date":"2018-07-09","kind":"sale","acquired":false,"shares":272,"price":84.94,"value":23103.68,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-18-042326","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1688865/000120919118042326/doc4.xml","form_type":"4"}},{"id":3869393,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":64973,"kind":"person","name":"Alenson Carman","position":1,"cik":"0001688865","reported_name":"Alenson Carman","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Common stock","published_at":"2018-07-11T16:23:54.000Z","date":"2018-07-09","kind":"exercise","acquired":true,"shares":272,"price":52.29,"value":14222.88,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":272,"source":{"system":"sec-edgar","filing":"0001209191-18-042326","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1688865/000120919118042326/doc4.xml","form_type":"4"}},{"id":4047978,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":64973,"kind":"person","name":"Alenson Carman","position":1,"cik":"0001688865","reported_name":"Alenson Carman","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Restricted stock units","published_at":"2018-02-20T16:05:21.000Z","date":"2018-02-16","kind":"grant","acquired":true,"shares":2370,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The restricted stock units were granted on February 16,2018. The shares underlying the restricted stock units will vest in three equal annual installments on February 16, 2019, 2020 and 2021. Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The restricted stock units were granted on February 16,2018. The shares underlying the restricted stock units will vest in three equal annual installments on February 16, 2019, 2020 and 2021. Vested shares will be delivered to the reporting person within three business days after such shares become vested."}],"balance_after":2370,"derivative":{"underlying":"Common stock","underlying_shares":2370},"source":{"system":"sec-edgar","filing":"0001209191-18-011251","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1688865/000120919118011251/doc4.xml","form_type":"4"}},{"id":4047977,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":64973,"kind":"person","name":"Alenson Carman","position":1,"cik":"0001688865","reported_name":"Alenson Carman","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Restricted stock units","published_at":"2018-02-20T16:05:21.000Z","date":"2018-02-16","kind":"grant","acquired":true,"shares":2800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"All of the restricted stock units will vest on February 16, 2020. Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"All of the restricted stock units will vest on February 16, 2020. Vested shares will be delivered to the reporting person within three business days after such shares become vested."}],"balance_after":2800,"derivative":{"underlying":"Common stock","underlying_shares":2800},"source":{"system":"sec-edgar","filing":"0001209191-18-011251","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1688865/000120919118011251/doc4.xml","form_type":"4"}},{"id":4047976,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":64973,"kind":"person","name":"Alenson Carman","position":1,"cik":"0001688865","reported_name":"Alenson Carman","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Stock option (right to buy)","published_at":"2018-02-20T16:05:21.000Z","date":"2018-02-16","kind":"grant","acquired":true,"shares":9480,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on February 16, 2018. The shares underlying this option vest as to 25% of the underlying shares on February 16, 2019, with the remaining 75% vesting in 36 equal monthly installments thereafter."}],"balance_after":9480,"derivative":{"exercise_price":77.7,"expiration_date":"2028-02-15","underlying":"Common stock","underlying_shares":9480},"source":{"system":"sec-edgar","filing":"0001209191-18-011251","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1688865/000120919118011251/doc4.xml","form_type":"4"}},{"id":4088237,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":64973,"kind":"person","name":"Alenson Carman","position":1,"cik":"0001688865","reported_name":"Alenson Carman","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Stock option (right to buy)","published_at":"2018-01-26T16:23:39.000Z","date":"2018-01-12","kind":"exercise","acquired":false,"shares":2150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on November 7, 2016. The shares underlying this option vest as to 25% of the underlying shares on November 7, 2017, with the remaining 75% vesting in 36 equal monthly installments thereafter."}],"balance_after":12850,"derivative":{"exercise_price":52.29,"expiration_date":"2026-11-06","underlying":"Common stock","underlying_shares":2150},"source":{"system":"sec-edgar","filing":"0001209191-18-005587","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1688865/000120919118005587/doc4.xml","form_type":"4"}},{"id":4088236,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":64973,"kind":"person","name":"Alenson Carman","position":1,"cik":"0001688865","reported_name":"Alenson Carman","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Common stock","published_at":"2018-01-26T16:23:39.000Z","date":"2018-01-12","kind":"sale","acquired":false,"shares":2150,"price":75,"value":161250.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-18-005587","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1688865/000120919118005587/doc4.xml","form_type":"4"}},{"id":4088235,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":64973,"kind":"person","name":"Alenson Carman","position":1,"cik":"0001688865","reported_name":"Alenson Carman","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Common stock","published_at":"2018-01-26T16:23:39.000Z","date":"2018-01-12","kind":"exercise","acquired":true,"shares":2150,"price":52.29,"value":112423.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":2150,"source":{"system":"sec-edgar","filing":"0001209191-18-005587","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1688865/000120919118005587/doc4.xml","form_type":"4"}},{"id":4427912,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":64973,"kind":"person","name":"Alenson Carman","position":1,"cik":"0001688865","reported_name":"Alenson Carman","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Restricted stock units","published_at":"2017-02-23T16:05:42.000Z","date":"2017-02-21","kind":"grant","acquired":true,"shares":3300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"kind","element":"transactionCoding","label":"F2","text":"All of the restricted stock units will vest on February 21, 2019. Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"All of the restricted stock units will vest on February 21, 2019. Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"All of the restricted stock units will vest on February 21, 2019. Vested shares will be delivered to the reporting person within three business days after such shares become vested."}],"balance_after":3300,"derivative":{"underlying":"Common stock","underlying_shares":3300},"source":{"system":"sec-edgar","filing":"0001209191-17-013738","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1688865/000120919117013738/doc4.xml","form_type":"4"}},{"id":4562205,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":64973,"kind":"person","name":"Alenson Carman","position":1,"cik":"0001688865","reported_name":"Alenson Carman","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Stock option (right to buy)","published_at":"2016-11-09T16:51:00.000Z","date":"2016-11-07","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on November 7, 2016. The shares underlying this option vest as to 25% of the underlying shares on November 7, 2017, with the remaining 75% vesting in 36 equal monthly installments thereafter."}],"balance_after":15000,"derivative":{"exercise_price":52.29,"expiration_date":"2026-11-06","underlying":"Common stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-16-149075","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1688865/000120919116149075/doc4.xml","form_type":"4"}}]}